首页> 外文期刊>Iranian journal of pediatrics >Cost-Effectiveness Analysis of Pulse Oximetry Screening in the Full-Term Neonates for Diagnosis of Congenital Heart Disease: A Systematic Review
【24h】

Cost-Effectiveness Analysis of Pulse Oximetry Screening in the Full-Term Neonates for Diagnosis of Congenital Heart Disease: A Systematic Review

机译:全术新生儿脉冲血氧筛查成本效果分析,以诊断先天性心脏病:系统综述

获取原文
           

摘要

Context: Congenital heart defect (CHD) is a leading cause of mortality by birth defects with significant social and economic burden. Pulse oximetry as a safe and non-invasive screening method, and recently its potential for early detection of CHD improved neonatal health outcomes. Objectives: The aim of this study was to systematically review economic evaluation studies that compared pulse oximetry with current programs to diagnose early detection of CHD in full-term newborns. Data Sources: A systematic review was conducted according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, and related articles published from 1995 up to March 2020 were searched in different databases (MEDLINE, EMBASE, PubMed, Science Direct, Google Scholar, Scopus, NHS EED, Science Citation Index, MagIran, Cochrane Library, EconLit and SID). The articles were selected based on inclusion and exclusion criteria. Consolidated health economic evaluation reporting standards (CHEERS) statement checklist was used to qualitatively evaluate the papers. Overall, 7 articles were included in the study. Results: Timely diagnosis was considered as main effectiveness health outcome in most studies. The highest and lowest values of incremental cost-effectiveness ratio (in two-phase studies) were €139,000 and $100 per infant in the Netherlands and Colombia respectively; and (in one-phase studies) were £24,000 and £1,489 per infant both belonging to the UK. Implementing pulse oximetry method concurrent with the clinical examination is more cost-effective. The reviewed studies had been conducted in high-income and upper middle-income countries; therefore, when the results are generalizing by policy makers in different health systems, a substantial precaution approach is needed.
机译:背景:先天性心脏缺陷(CHD)是出生缺陷具有重要社会和经济负担的死亡原因。脉冲血氧滴定作为一种安全和无侵入性筛选方法,最近其早期检测CHD改善新生儿健康结果的可能性。目的:本研究的目的是系统地审查经济评估研究,使脉搏血液与当前计划进行诊断,以诊断全术语新生儿的早期检测。数据来源:根据首选报告项目进行系统审查,用于系统评价和荟萃分析(PRISMA)指南(PRISMA)指导方针,并在1995年至2020年发布的相关文章进行了搜查(Medline,Embase,PubMed,Science Direct,谷歌学者,Scopus,NHS EED,科学引文,Magiran,Cochrane图书馆,Econlit和SID)。基于包含和排除标准选择制品。综合健康经济评估报告标准(CHEERS)声明清单用于定性评估论文。总体而言,该研究中包含7篇文章。结果:在大多数研究中,及时诊断被认为是主要有效性健康结果。荷兰和哥伦比亚的最高增量成本效益率(两期研究)的最高和最低值分别为139,000欧元和每婴幼儿100欧元; (在一期研究中)为每幼英国的24,000英镑和1,489英镑。实施脉搏血氧法同时与临床检查更具成本效益。审查的研究是在高收入和高收入国家进行的;因此,当结果在不同健康系统中的决策者概括时,需要大量的预防措施。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号